FDA approves patch to treat depression in adults

02/28/2006 | MSNBC

The FDA has approved Emsam, a selegiline transdermal patch to treat depression in adults, but the drug will have to carry a black-box warning for suicide. The patch is a product of Bristol-Myers Squibb and Somerset Pharmaceuticals, which is a joint venture between Mylan Laboratories and Watson Pharmaceuticals.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT